A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease

NCT06164730

Status	RECRUITING
Phase	Phase 1
Sponsor	Verve Therapeutics, Inc.
Enrollment	85 participants

Key Eligibility Criteria

Inclusion (1)

- Diagnosis of HeFH or premature CAD

Exclusion (4)

- Homozygous familial hypercholesterolemia
- Active or history of chronic liver disease
- Current treatment with PCSK9 inhibitor or prior treatment within specified timeframe
- Clinically significant or abnormal laboratory values as defined by the protocol

Locations (22 total)

Clinical Study Center, Dothan, Alabama, United States
Clinical Study Center, Pomona, California, United States
Clinical Study Center, Boca Raton, Florida, United States
... and 19 more locations